Project description
The aim of the research we propose is to answer the question - does COVID-19 in patients with UC lead to permanent changes in the composition of the intestinal microbiota, and thus - the metabolome, predisposing to the symptoms of irritable bowel syndrome? We are extremely interested in the issue of how the microbiota and its metabolome in patients with CU who have had a coronavirus infection and present IBS symptoms differ from those who have IBS symptoms and have not been infected? Is the picture of the microbiota of patients with IBS who do not suffer from UC similar? How does SARS-CoV-2 determine the appearance of IBS symptoms? As there are currently no reports on this subject, there is space to supplement this knowledge.
The results of the study would certainly broaden the knowledge about the pathogenesis of IBS itself, which remains unclear. In addition, they could perhaps contribute to the development of a new therapeutic approach for patients for whom there is no effective treatment.
Poland's winning projects
Innovative Neuroprotection: The Impact of Extracellular Vesicles from Commensal Bifidobacterium Strains on Blood-Brain Barrier Protection in Inflammation
Assessment of the intestinal microbiome enterotype and the ability to break down starch in a weight reduction program using nutritional intervention and probiotic therapy in obese women
Effect of fecal microbiota transfer on progression of Parkinson Disease
Assessment of changes in the intestinal microbiota of children with ulcerative colitis under the influence of glutamine by nanopore sequencing: a randomized trial
Treatment of patients with Irritable Bowel Syndrome (IBS) by means of intestinal microbiota transplantation - assessment of the effectiveness of therapy and its effect on the change of intestinal microbiome